The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Inspired by Pfizer’s response to the COVID pandemic, Miguel Agreda ’25 brought his skills as a joint-degree MBA/MPH student ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...